Form 4: Replimune Group Executive Konstantinos Xynos Reports Acquisition of Shares and Stock Options

Konstantinos Xynos, Chief Medical Officer of Replimune Group, reports acquiring shares through restricted stock units and stock options.

Summary

• On April 1, 2024, Konstantinos Xynos, the Chief Medical Officer of Replimune Group, Inc., acquired 26,665 shares of common stock through the settlement of restricted stock units (RSUs) at a price of $0.
• Following this transaction, Xynos directly owns 139,379 shares of Replimune Group, Inc.
• Additionally, on the same date, Xynos acquired an option to purchase 80,000 shares of common stock at an exercise price of $7.73, which vests over time.
• These stock options expire on April 1, 2034.
• After the transaction, Xynos directly owns 80,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of shares and options by an executive is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of shares and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for both the RSUs and stock options suggest a long-term commitment from the executive to the company's success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the perceived alignment of interests with management.

Key Dates